Loading
A phase 2 trial of Fludarabine and Cyclophosphamide in diffuse large B-cell lymphoma, run by Allogene Therapeutics, now recruiting.
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL is a phase 2 interventional study registered as NCT06500273 by Allogene Therapeutics, with 250 participants planned, started 2024-06-18 and due to reach its primary completion in 2027-12. Interventions recorded: cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide and Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Allogene Therapeutics, Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Allogene Therapeutics, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Fludarabine, Cyclophosphamide, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/